New drug combo offers hope for Hard-to-Treat blood cancer
NCT ID NCT06160843
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This study tests whether combining two drugs, pembrolizumab and olaparib, can shrink tumors or slow the growth of peripheral T-cell lymphoma (PTCL) that has returned or not responded to prior therapy. About 24 adults will receive the drugs in 3-week cycles for up to 2 years. The main goal is to see how many patients achieve a complete or partial response, while also monitoring side effects and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Centre, Singapore
RECRUITINGSingapore, 168583, Singapore
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.